Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its target price decreased by equities research analysts at SVB Leerink from $60.00 to $56.00 in a research note issued on Friday, Marketbeat.com reports. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. SVB Leerink’s target price points to a potential upside of 12.16% from the company’s previous close.
Several other equity analysts also recently commented on the company. Jefferies Financial Group upgraded Blueprint Medicines from a “hold” rating to a “buy” rating and cut their target price for the stock from $88.00 to $78.00 in a research report on Wednesday, June 1st. Stifel Nicolaus raised their target price on Blueprint Medicines from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, March 4th. Piper Sandler cut their target price on Blueprint Medicines from $84.00 to $65.00 and set a “neutral” rating for the company in a research report on Wednesday, May 18th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Blueprint Medicines in a research report on Friday, June 10th. Finally, Citigroup downgraded Blueprint Medicines from a “neutral” rating to a “sell” rating and cut their price objective for the company from $68.00 to $41.00 in a research report on Thursday, June 9th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $89.54.
Shares of BPMC stock opened at $49.93 on Friday. The stock has a 50 day moving average of $55.61 and a two-hundred day moving average of $68.56. Blueprint Medicines has a 12 month low of $43.46 and a 12 month high of $117.86. The company has a market capitalization of $2.97 billion, a P/E ratio of -4.52 and a beta of 0.97.
Blueprint Medicines (NASDAQ:BPMC – Get Rating) last posted its earnings results on Tuesday, May 3rd. The biotechnology company reported ($1.79) EPS for the quarter, hitting the consensus estimate of ($1.79). The business had revenue of $62.70 million during the quarter, compared to the consensus estimate of $39.98 million. Blueprint Medicines had a negative return on equity of 35.24% and a negative net margin of 293.97%. Blueprint Medicines’s revenue was up 190.3% on a year-over-year basis. During the same quarter last year, the company earned ($1.72) EPS. On average, equities analysts expect that Blueprint Medicines will post -8.06 EPS for the current year.
In other Blueprint Medicines news, CEO Jeffrey W. Albers sold 5,000 shares of Blueprint Medicines stock in a transaction dated Wednesday, April 6th. The stock was sold at an average price of $70.11, for a total transaction of $350,550.00. Following the transaction, the chief executive officer now directly owns 183,243 shares in the company, valued at $12,847,166.73. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Percy H. Carter sold 1,908 shares of Blueprint Medicines stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $59.76, for a total value of $114,022.08. Following the transaction, the insider now owns 28,685 shares in the company, valued at $1,714,215.60. The disclosure for this sale can be found here. 3.34% of the stock is owned by insiders.
A number of hedge funds have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. lifted its holdings in Blueprint Medicines by 19.8% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 906 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 150 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in Blueprint Medicines by 7.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,536 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 168 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its holdings in Blueprint Medicines by 0.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 35,131 shares of the biotechnology company’s stock worth $3,763,000 after acquiring an additional 175 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Blueprint Medicines by 15.2% during the fourth quarter. Van ECK Associates Corp now owns 1,335 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 176 shares in the last quarter. Finally, Exane Derivatives lifted its holdings in shares of Blueprint Medicines by 45.8% in the first quarter. Exane Derivatives now owns 567 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 178 shares in the last quarter. Hedge funds and other institutional investors own 99.69% of the company’s stock.
About Blueprint Medicines: (Get Rating)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.
Read More:
Receive News & Ratings for Blueprint Medicines Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Blueprint Medicines and related companies with MarketBeat.com’s FREE daily email newsletter.
.